Study: Treatment for Follicular Lymphoma Patients Must be Individualized

A recent study examined three different follicular lymphoma (FL) patients to try to better understand how the disease presents differently for different individuals. Ultimately, this study has reiterated the importance…

Continue Reading Study: Treatment for Follicular Lymphoma Patients Must be Individualized
Study: Felty’s Syndrome Presents Differently in Pediatric Patients
source: pixabay.com

Study: Felty’s Syndrome Presents Differently in Pediatric Patients

According to a study published in BMC Pediatrics, the rare disease known as Felty's syndrome is primarily known to affects adults between the ages of 50 and 70, but on very rare…

Continue Reading Study: Felty’s Syndrome Presents Differently in Pediatric Patients
XPOVIO Being Evaluated for Treatment of Diffuse Large B-Cell Lymphoma
Source: https://pixabay.com/en/white-blood-cell-cell-blood-cell-543471/

XPOVIO Being Evaluated for Treatment of Diffuse Large B-Cell Lymphoma

Karyopharm, a pharmaceutical company based in Newton, Massachusetts, has submitted a New Drug Application to the FDA for their drug XPOVIO, which is meant for the treatment of diffuse large…

Continue Reading XPOVIO Being Evaluated for Treatment of Diffuse Large B-Cell Lymphoma
For This 4 Year Old With Acute Lymphoblastic Leukemia, Fear of Infection Has Kept Him From Being a Kid
vitalworks / Pixabay

For This 4 Year Old With Acute Lymphoblastic Leukemia, Fear of Infection Has Kept Him From Being a Kid

According to a story from mirror.co.uk, Jack Ruddock, aged four, had always been an endearing and good spirited child, but his life took a dramatic turn when he was hospitalized…

Continue Reading For This 4 Year Old With Acute Lymphoblastic Leukemia, Fear of Infection Has Kept Him From Being a Kid

Study Suggests Female Cancer Patients Have Better Outcomes After Treatment, Experience Worse Side Effects

According to a publication from EurekAlert, a recent study helmed by the Royal Marsden NHS Foundation Trust suggests that female cancer patients tend to live slightly longer following treatment than…

Continue Reading Study Suggests Female Cancer Patients Have Better Outcomes After Treatment, Experience Worse Side Effects

Early Trial Data for Experimental Multiple Myeloma Drug Shows Promise

According to a story from EurekAlert!, the biopharmaceutical company Celgene Corporation and the gene therapy company bluebird bio, inc. recently announced that the interim results for a Phase 1 clinical…

Continue Reading Early Trial Data for Experimental Multiple Myeloma Drug Shows Promise

In-Patient Hospitalization vs. At-Home Programs: Will Doctors Be Making House Calls Again?

Ash Clinical News recently interviewed Dr. Bruce Leff of Johns Hopkins in connection with “hospital-at-home”, one of the major changes occurring in hospital care. Dr. Leff and his team at…

Continue Reading In-Patient Hospitalization vs. At-Home Programs: Will Doctors Be Making House Calls Again?

Targeted drug for leukemia tested at Penn Medicine helps patients live longer

The oral inhibitor drug gilteritinib (XOSPATA®) was recently approved by the USFDA based on interim results of the clinical trial ADMIRAL according to an article in EurekAlert for Science News. A total of 371 adult patients…

Continue Reading Targeted drug for leukemia tested at Penn Medicine helps patients live longer
Sprycel Approved by FDA for Pediatric Ph+ Acute Lymphoblastic Leukemia Patients
Source: Pixabay

Sprycel Approved by FDA for Pediatric Ph+ Acute Lymphoblastic Leukemia Patients

Thanks to a Phase 2 trial, pediatric patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or Ph+ ALL, now have a new treatment option. The FDA has announced approval of Sprycel…

Continue Reading Sprycel Approved by FDA for Pediatric Ph+ Acute Lymphoblastic Leukemia Patients

Experimental Treatment For Small Cell Lung Cancer Receives Orphan Drug Designation

According to a story from pm360online.com, the drug development company Cytori Therapeutics recently announced that its investigational product ATI-1123 has been granted Orphan Drug designation from the US Food and…

Continue Reading Experimental Treatment For Small Cell Lung Cancer Receives Orphan Drug Designation

Melflufen Could be a New Treatment Option for Multiple Myeloma

According to a story from Hematology Times, a medicine called melflufen, of the alkylating peptide class, appears to be effective in treatment resistant multiple myeloma. In a Phase 2 trial,…

Continue Reading Melflufen Could be a New Treatment Option for Multiple Myeloma
Close Menu